Introduction
Septic patients frequently experience cognitive dysfunction that persists beyond hospital discharge, impairing survivors' quality of life and ability to return to work (1) (2) (3) . This cognitive impairment has been largely attributed to brain injury occurring early in sepsis, arising from pathogenic processes including cerebral microvascular thrombosis, metabolic derangements, and IL-1β-dependent neuroinflammation (4) (5) (6) (7) (8) . Less is known about the long-term functional effects of sepsis on the electrophysiological and molecular neuronal pathways responsible for learning.
Classic neurosurgical studies have identified the hippocampus as the anatomic center of memory. Learning requires synaptic plasticity between key hippocampal neuronal networks, including the strengthening of cornu ammonis region 3 (CA3) to cornu ammonis region 1 (CA1) neuronal connections through a process called longterm potentiation (LTP), the key molecular mechanism driving spatial memory (9) . Hippocampal LTP is dependent on the neuronal growth factor brain-derived neurotrophic factor (BDNF), as demonstrated by the induction of cognitive impairment by experimental BDNF sequestration (10) . Interestingly, experimental and human sepsis has been associated with hippocampal pathology, including acute dysfunction of the hippocampal blood-brain barrier as well as later loss of hippocampal volumes in sepsis survivors (11) (12) (13) .
There is increasing appreciation for the importance of the endothelial glycocalyx in sepsis pathophysiology. The glycocalyx is a ubiquitous endovascular layer enriched in heparan sulfate, a linear polysaccharide of repeating glucosamine-hexuronic (iduronic or glucuronic) acid disaccharide units. These disaccharides may be sulfated at specific sites (including the 2-O position of iduronic acid and/or the 6-O or N position of glucosamine), imparting a domain patterning of negative charge. During sepsis, the glycocalyx is fragmented, releasing heparan sulfate hexa-and octasaccharides into the bloodstream (14) (15) (16) . These fragments have the capacity to interact with soluble proteins (such as growth factors) with remarkable specificity through sulfation-based electrostatic interactions, influencing a variety of homeostatic and/or pathologic signaling pathways (17) . Shed fragments circulate for several days after sepsis onset and correlate with clinically significant outcomes including acute kidney and lung injury (15, 18) .
Septic patients frequently develop cognitive impairment that persists beyond hospital discharge. The impact of sepsis on electrophysiological and molecular determinants of learning is underexplored. We observed that mice that survived sepsis or endotoxemia experienced loss of hippocampal long-term potentiation (LTP), a brain-derived neurotrophic factor-mediated (BDNF-mediated) process responsible for spatial memory formation. Memory impairment occurred despite preserved hippocampal BDNF content and could be reversed by stimulation of BDNF signaling, suggesting the presence of a local BDNF inhibitor. Sepsis is associated with degradation of the endothelial glycocalyx, releasing heparan sulfate fragments (of sufficient size and sulfation to bind BDNF) into the circulation. Heparan sulfate fragments penetrated the hippocampal bloodbrain barrier during sepsis and inhibited BDNF-mediated LTP. Glycoarray approaches demonstrated that the avidity of heparan sulfate for BDNF increased with sulfation at the 2-O position of iduronic acid and the N position of glucosamine. Circulating heparan sulfate in endotoxemic mice and septic humans was enriched in 2-O-and N-sulfated disaccharides; furthermore, the presence of these sulfation patterns in the plasma of septic patients at intensive care unit (ICU) admission predicted persistent cognitive impairment 14 days after ICU discharge or at hospital discharge. Our findings indicate that circulating 2-O-and N-sulfated heparan sulfate fragments contribute to septic cognitive impairment.
Circulating heparan sulfate fragments mediate septic cognitive dysfunction 1 Figure 1A ; supplemental material available online with this article; https://doi. org/10.1172/JCI124485DS1). Endotoxemic mice displayed sickness behavior for 3 days, followed by resumption of normal behavior and weight gain by day 7 (Supplemental Figure 1B) . To determine whether post-septic mice had memory deficits that persisted despite resumption of normal activity, we performed hippocampus-dependent neurobehavioral testing (contextual fear conditioning) on WT C57BL/6 mice 7 days after i.p. LPS or saline (control) injection. Contextual memory was apparent in saline-treated mice but was impaired in post-LPS-treated mice ( Figure 1A ). This post-LPS deficit in memory coincided with loss of hippocampal Given the importance of the growth factor BDNF to cognition, as well as the ability of circulating heparan sulfate fragments to influence growth factor signaling, we hypothesized that hippocampal penetration of circulating heparan sulfate fragments leads to sequestration of BDNF, impairing LTP and inducing septic cognitive impairment. In this study, we used multimodal ex vivo, in vivo, and human studies to demonstrate that N-and 2-O-sulfated heparan sulfate fragments are released into the circulation during sepsis and inhibit BDNF-mediated hippocampal LTP, leading to cognitive dysfunction in both mice and humans.
Results and Discussion
To establish a model of septic cognitive dysfunction, we induced endotoxemia in 8-to 12-week-old male and female C57BL/6 mice Living hippocampal slices isolated from mice 7 days after i.p. LPS administration (as compared with saline) showed impaired LTP, the BDNF-dependent neuronal process responsible for spatial memory. (C) A similar loss of LTP was also seen 7 days after CLP, a model of polymicrobial peritonitis-induced sepsis. Loss of LTP occurred 7 days after LPS, despite (D) maintenance of hippocampal BDNF content and (E) preserved responsiveness to excess (100 ng/ml) exogenous BDNF. (F) Maintenance of the BDNF-responsive molecular machinery of learning after sepsis was further demonstrated by reversal of memory deficits in post-LPS mice treated daily with 7,8-DHF (5 μg/g i.p.), a direct agonist of the BDNF receptor TrkB. *P < 0.05 and **P < 0.01, by t test. For LTP measurements, the left panels represent the mean ± SEM of groups; the right panels represent the average change from baseline over the final 10 minutes of measurement (each data point represents a unique biological replicate). TBS, theta burst stimulation.
Volume 129 Number 4 April 2019 Figure 2 ) as well as the ability to induce LTP in response to exogenous BDNF (100 ng/ml, Figure 1E ). Treatment of endotoxemic mice with 7,8-dihydroxyflavone (7,8-DHF) (5 μg/g BW administered daily via i.p. injection), a well-tolerated selective agonist of the BDNF receptor tyrosine receptor kinase B (TrkB), prevented loss of memory by day 7, as demonstrated by normalization of contextual fear conditioning ( Figure 1F ). Taken together, these LTP, as measured using 300-μm-thick living hippocampal brain slices isolated from 8-to 12-week-old C57BL/6 mice 7 days after LPS (or saline) treatment ( Figure 1B ). We observed a similar loss of LTP in mice 7 days after cecal ligation and puncture (CLP) ( Figure  1C , CLP or sham), a widely used model of polymicrobial peritonitis-induced sepsis. Intriguingly, we observed that post-LPS hippocampi maintained BDNF content ( Figure 1D and Supplemental pal heparan sulfate content at the point of peak circulating heparan sulfate (1 day after LPS treatment) ( Figure 2C ). Interestingly, the accumulation of hippocampal heparan sulfate persisted for 7 days after LPS treatment, a time point characterized by impaired cognition ( Figure 1A ). The persistence of brain heparan sulfate has been recognized in other neurodegenerative disease states, such as Alzheimer's dementia (21) (22) (23) . Hippocampal heparan sulfate content eventually normalized in mice 14 days after LPS treatment (compared with mice 14 days after saline treatment), which was coincident with improvement in cognition (Supplemental Figure 4) . We have previously demonstrated that circulating heparan sulfate oligosaccharides can influence growth factor signaling by electrostatically binding positively charged residues of growth factor ligands (19) . To determine whether hippocampus-penetrating heparan sulfate fragments interfere with BDNF, the neurotrophin responsible for hippocampal LTP, we isolated hippocampal slices from healthy (non-septic) 8-to 12-week-old C57BL/6 male and female mice and measured LTP in the presence or absence of highly sulfated heparan sulfate (heparin) octasaccharides, approximating the known size and sulfation pattern of circulating heparan sulfate fragments after sepsis (14) . Exposure of hipfindings indicate that post-endotoxemic/post-septic mice have impaired memory and loss of LTP, despite the presence of BDNF within the hippocampus and persistence of hippocampal responsiveness to TrkB activation, suggesting induction of a competitive inhibitor of BDNF within the septic hippocampus.
Our group and others have shown that highly sulfated heparan sulfate hexa-to octasaccharide fragments are shed into the plasma in animal (19) and human (14) sepsis as a consequence of endothelial glycocalyx degradation. We confirmed these findings using high-sensitivity mass spectrometry multiple reaction monitoring (MRM) (19) analyses of plasma collected after i.p. LPS treatment in mice (Figure 2A ) and in a separate cohort of human patients with sepsis, who were enrolled in the Molecular Epidemiology of SepsiS in the Intensive Care Unit (MESSI) study ( Figure 2B) . Consistent with the known ability of ultra-low-molecular-weight heparins to cross the blood-brain barrier in healthy mice (20) , we observed that circulating heparan sulfate fragments also penetrated the blood-brain barrier, as i.v. administered fluorescein-labeled heparan sulfate octasaccharides were observed in the hippocampus ( Figure 2D ) and cortex (Supplemental Figure 3) in both septic and non-septic mice. Likewise, we observed an increase in hippocam- 
including NS, NS2S, NS6S, and TriS disaccharides) and 2-O sulfation (NS2S, 2S, 2S6S, and TriS). Control patients were normal blood donors (n = 9). (E)
Mouse hippocampi after sepsis were enriched in N-and 2-O sulfation on day 7 (n = 3 for all time points and groups). (F) Patients who showed moderate to severe cognitive impairment (MoCA score <21 or cognitive inability to perform the test, n = 6) at the time of hospital discharge (or on day 14 after ICU discharge) were those who previously had (at the time of ICU admission, day = 0) circulating heparan sulfate enriched in NS2S disaccharides or a combination of NS, NS2S, and NS6S disaccharides. n = 14 patients with normal to mild impairment. Horizontal lines in the boxes represent the median, borders represent the 25th and 75th percentiles, and whiskers represent the upper and lower adjacent values (1.5 × interquartile range, Tukey's method). Outside values were included in the analyses. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by t test for single comparisons (B-D), ANOVA with Tukey's correction for multiple comparisons (E), or Wilcoxon rank-sum test (F). for BDNF binding, we used a glycosaminoglycan microarray (glycoarray) composed of 52 heparan oligosaccharides of varying sulfation patterns (24) . This approach revealed that BDNF-avid oligosaccharides commonly contained disaccharides with both N-and 2-O sulfation sequences ( Figure 3B and Supplemental Figure 6 ). Intriguingly, circulating heparan sulfate fragments collected from post-LPS-treated mice ( Figure 3C ) and septic humans ( Figure 3D , Supplemental Figure 7 , and Supplemental Table 1 ) were similarly enriched in N and 2-O sulfation sequences on mass spectrometry MRM analysis. This enrichment in N and O sulfation was observed in the hippocampi of post-septic mice and persisted for 7 days (Figure 3E and Supplemental Table 2 ), indicating that mice maintained BDNF-avid heparan sulfate fragments within their hippocampi at time points coincident with post-septic cognitive impairment. We performed additional glycoarray experiments to define the avidity of heparan sulfate oligosaccharides for pro-BDNF, a proenzyme incapable of promoting LTP (25) . We observed no pro-BDNF binding to any heparan sulfate oligosaccharide sequence (Supplemental Figure 8A ), suggesting that the cleavage of pro-BDNF to active BDNF exposes a heparan sulfate binding site. Other known heparan sulfate binding proteins (e.g., antithrombin III, platelet factor 4) bound to heparan sulfate sequences distinct from those that bound BDNF. Similarly, the heparan sulfate 10e4 antibody (26) failed to bind BDNF-avid sequences (Supplemental Figure 8, B-D) . We leveraged this inability of the 10e4 antibody to bind BDNFavid sequences to demonstrate that sequestration of non-BDNFavid heparan sulfate sequences failed to prevent loss of LTP (Supplemental Figure 9 ), further confirming the sulfation sequence specificity of the observed BDNF-inhibitory effect of heparan sulfate.
To determine the translational relevance of our findings, we measured heparan sulfate in plasma samples collected on day 0 (i.e., at presentation to the intensive care unit [ICU]) from septic patients enrolled in the Neurocognitive Impairment in Respiratory Failure and Shock (NIRFS) study of the MESSI cohort (Table 1) to determine whether the presence of circulating N-and 2-O-sulfated heparan sulfate predicted cognitive impairment in sepsis. NIRFS patients with persistent cognitive impairment after sepsis (as quantified by a Montreal Cognitive Assessment [MoCA] score <21 or a cognitive inability to perform the test either at hospital discharge or 14 days after ICU discharge) were those who had increased circulating N-and 2-O-sulfated heparan sulfate at the time of ICU admission ( Figure 3F and Supplemental Table 3 ). Taken together, our findings demonstrate that the presence of circulating NS-and/or 2S-enriched, BDNF-avid heparan sulfate fragments at sepsis onset predicts cognitive impairment up to 2 weeks after ICU discharge.
In summary, our findings demonstrate that septic neurocognitive dysfunction is not only a consequence of inflammatory or ischemic brain injury but may also arise from septic interference with biologic processes (i.e., hippocampal BDNF/TrkB signaling) necessary for memory and cognition. Detection of circulating N-and 2-O-sulfated heparan sulfates may therefore allow the identification of septic patients at high risk of prolonged cognitive impairment, enabling the future development (and personalized implementation) of sulfation sequence-targeted therapeutics to improve memory and other patient-centered outcomes in sepsis survivors. pocampal slices to highly sulfated octasaccharides inhibited LTP as compared with matched control slices isolated from the same mice ( Figure 2E ). Heparan sulfate-mediated inhibition of LTP could be reversed by the downstream activation of TrkB, as octasaccharides were unable to impede LTP when coadministered with 7,8-DHF ( Figure 2E ). This suggests that the negative effect of heparan sulfate on hippocampal LTP was mediated by inhibition of BDNF/TrkB signaling rather than by any nonspecific injurious effect of the glycosaminoglycan. These findings support the idea that sepsis-induced circulating heparan sulfate fragments penetrate the septic hippocampus and inhibit BDNF-specific molecular mechanisms of learning.
Heparan sulfate disaccharides may be sulfated at the N and 6-O positions of glucosamine or the 2-O position of iduronic acid ( Figure 3A) , imparting a domain patterning of negative charge that determines the ability of the heparan sulfate polysaccharide to selectively bind soluble ligands. We performed surface plasmon resonance (SPR), a technique that allows for quantification of glycosaminoglycan-protein interaction, to identify the sulfation sites that participate in heparan sulfate-BDNF binding. We found that heparan sulfate fragments bound BDNF in a length-and sulfation-dependent manner (Supplemental Figure 5) . Since SPR does not inform the precise sequence or pattern of sulfation necessary A n = 17; 3 patients were unable to complete the MoCA because of severe cognitive impairment. APACHE, acute physiologic assessment and chronic health evaluation.
